Mark E Bensink
Overview
Explore the profile of Mark E Bensink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swart E, Peasah S, Huang Y, Bensink M, Greco M, Manolis C, et al.
J Manag Care Spec Pharm
. 2025 Feb;
31(3):236-244.
PMID: 40021466
Background: Migraine prevalence is estimated to be 15% (approximately 50 million people) in the United States, posing a significant burden on the health care system and a top cause of...
2.
Goldschmidt D, Bensink M, Zhou Z, Shi S, Lin Y, Shi L
PLoS One
. 2024 Dec;
19(12):e0315302.
PMID: 39671357
Introduction: Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disease that can lead to reduced kidney function and kidney failure (KF). The objective of this study was to describe the...
3.
Zhou Z, Bensink M, Hazra N, Xu C, Hendry B, Sharpe C, et al.
Pharmacoecon Open
. 2024 Sep;
9(1):83-92.
PMID: 39305448
Background: Immunoglobulin A nephropathy (IgAN) is a rare progressive disease that can lead to kidney failure. The current study aimed to estimate health state utility values for IgAN from a...
4.
Multani J, Urman R, Park A, Gill K, Vuvu F, Sun K, et al.
Headache
. 2024 Sep;
65(1):68-79.
PMID: 39248147
Objective: To assess changes in real-world use of acute and preventive medications for migraine over a 12-month follow-up period in the United States following initiation of the anti-calcitonin gene-related peptide...
5.
Urman R, Princic N, Vuvu F, Patel L, Oh S, Chandler D, et al.
Pain Ther
. 2024 Aug;
13(5):1299-1313.
PMID: 39177937
Introduction: Erenumab-aooe is approved for the preventive treatment of migraine in adults. Recent publications have evaluated migraine medication use during the 6 months after starting erenumab, but longer-term follow-up data...
6.
Khodavirdi A, Multani J, Oh S, Vuvu F, Bensink M, Stockl K, et al.
Front Neurol
. 2024 Aug;
15:1433423.
PMID: 39165264
Introduction: Migraine is a debilitating neurological disorder, with a wide range of symptoms and disease burden, underscoring the heterogeneity of patients' disease characteristics and treatment needs. To characterize the profile...
7.
Velez J, Thakker K, Bensink M, Lerma E, Lieblich R, Bunke C, et al.
Kidney360
. 2024 May;
5(8):1145-1153.
PMID: 38748483
No abstract available.
8.
Lerma E, Thakker K, Bensink M, Lieblich R, Bunke C, Gong W, et al.
Kidney360
. 2024 Feb;
5(3):427-436.
PMID: 38323871
No abstract available.
9.
Bensink M, Goldschmidt D, Zhou Z, Wang K, Lieblich R, Bunke C
Kidney Med
. 2024 Feb;
6(2):100760.
PMID: 38304582
Rationale & Objective: This study describes the epidemiology, characteristics, and clinical outcomes of patients with focal segmental glomerulosclerosis (FSGS)-attributed kidney failure in the US Renal Data System (USRDS) during 2008-2018,...
10.
Bensink M, Goldschmidt D, Zhou Z, Wang K, Lieblich R, Bunke M
Kidney Med
. 2024 Jan;
6(2):100759.
PMID: 38282694
Rationale & Objective: This study describes the epidemiology, characteristics, and outcomes of patients with immunoglobulin A nephropathy (IgAN)-attributed kidney failure in the US Renal Data System (USRDS) from 2008 to...